Clinical Trial Update: A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) [Phase 3]

View source ↗

Summary

A Phase 3 study comparing pembrolizumab plus epacadostat versus pembrolizumab plus placebo in unresectable or metastatic melanoma completed, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Epacadostat (epacadostat)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Incyte Corporation | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2019-05-15